Home » Authors » Aaron Lorenzo

Articles by Aaron Lorenzo

Versicor Plans Anidulafungin Esophageal Candidiasis NDA

March 19, 2003

By Aaron Lorenzo

With positive Phase III data in hand, Versicor Inc. reiterated plans to file a new drug application by the end of next month for its lead candidate, anidulafungin. (BioWorld Today)

Versicor Plans Anidulafungin Esophageal Candidiasis NDA

March 19, 2003

By Aaron Lorenzo

With positive Phase III data in hand, Versicor Inc. reiterated plans to file a new drug application by the end of next month for its lead candidate, anidulafungin. (BioWorld Today)

Genta Gains $40M Credit Facility From Late-Stage Partner Aventis

March 18, 2003

By Aaron Lorenzo

Investors Waking Up To Hypnion; Company Closes $47.5M Series B

March 18, 2003

By Aaron Lorenzo

Investors Waking Up To Hypnion; Company Closes $47.5M Series B

March 18, 2003

By Aaron Lorenzo

Genta Gains $40M Credit Facility From Late-Stage Partner Aventis

March 18, 2003

By Aaron Lorenzo

Inspire Increases Share Amount, Raises $67.5M For Eye Products

March 17, 2003

By Aaron Lorenzo

Inspire Increases Share Amount, Raises $67.5M For Eye Products

March 17, 2003

By Aaron Lorenzo

Cytokine PharmaSciences Signs Baxter To MIF Technology Deal

March 14, 2003

By Aaron Lorenzo

Cytokine PharmaSciences Signs Baxter To MIF Technology Deal

March 14, 2003

By Aaron Lorenzo

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...
IMV-101 shows promise for B-cell malignancies
BioWorld Science
IMV-101 is a new CAR T-cell therapy targeting CD19 developed by Suzhou Immunofoco Biotechnology Co. Ltd. for the potential treatment of B-cell malignancies and...